A citation-based method for searching scientific literature

Sehhoon Park, Beung-Chul Ahn, Sung Won Lim, Jong-Mu Sun, Hye Ryun Kim, Min Hee Hong, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon La Choi, Byoung Chul Cho, Myung-Ju Ahn. J Thorac Oncol 2018
Times Cited: 54



A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari, S C Wang, K D Wilner, J W Clark, S-H I Ou. Ann Oncol 2019
Times Cited: 169




List of shared articles



Times cited

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
56

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
N Girard, S Galland-Girodet, V Avrillon, B Besse, M Duruisseaux, J Cadranel, J Otto, A Prevost, B Roch, J Bennouna,[...]. ESMO Open 2022
2

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review.
Gianmarco Leone, Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Silvia Novello. Transl Lung Cancer Res 2020
0

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC.
Yi-Long Wu, Shun Lu, James Chih-Hsin Yang, Jianying Zhou, Takashi Seto, Myung-Ju Ahn, Wu-Chou Su, Noboru Yamamoto, Dong-Wan Kim, Jolanda Paolini,[...]. JTO Clin Res Rep 2022
0

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
12

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
20

Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib.
Long Xu, Xiaoxia Chen, Hong Huo, Yongye Liu, Xiaodan Yang, Dejian Gu, Mingming Yuan, Min Zhang, Rongrong Chen, Jiayin Wang,[...]. Front Med (Lausanne) 2021
1

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.
Amanda J W Gibson, Adrian Box, Winson Y Cheung, Michelle L Dean, Anifat A Elegbede, Desiree Hao, Aliyah Pabani, Randeep Sangha, Dafydd Gwyn Bebb. Curr Oncol 2022
0

ROS1 Targeted Therapies: Current Status.
Christine M Azelby, Mandy R Sakamoto, Daniel W Bowles. Curr Oncol Rep 2021
9


ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
S├ębastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
3

Evaluating entrectinib as a treatment option for non-small cell lung cancer.
Jiyun Lee, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. Expert Opin Pharmacother 2020
6